Skip to main content
Evidence Snapshot

Polyamine deacetylase HDAC10

CHEMBL5103 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5103
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Polyamine deacetylase HDAC10 as ChEMBL target CHEMBL5103, mapped to UniProt Q969S8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Polyamine deacetylase HDAC10
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5103
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q969S8
Polyamine deacetylase HDAC10
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Polyamine deacetylase HDAC10 matters

As of 2026-09-13

Polyamine deacetylase HDAC10 is reviewed as Polyamine deacetylase HDAC10 (UniProt Q969S8); the current evidence base includes 10 approved drugs, 645 compounds, and 275 assays, with lead potency reaching pChEMBL 10.3.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 645 compounds, and 275 assays for this target. The dominant activity type is IC50. CHEMBL2105763 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL2105763 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Polyamine deacetylase HDAC10 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q969S8, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

645
Total Compounds
275
Total Assays
10
Approved Drugs
IC50: 770.0, KI: 67.0, KD: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2105763
 10.3 Ki Clinical
No preferred name
CHEMBL3329621
 9.7 IC50 —
No preferred name
CHEMBL2105763
 9.3 IC50 Clinical
No preferred name
CHEMBL1796689
 9.3 IC50 —
No preferred name
CHEMBL3329622
 9.3 IC50 —

Approved Drugs

Structure Compound First Approval
GIVINOSTAT
CHEMBL1213492
 2024
PANOBINOSTAT
CHEMBL483254
 2015
BELINOSTAT
CHEMBL408513
 2014
ROMIDEPSIN
CHEMBL343448
 2009
BENDAMUSTINE
CHEMBL487253
 2008
VORINOSTAT
CHEMBL98
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5103